Skip to main content
Company profile
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc.

Pipeline4 assets

  • agenT-797agenT-797 / Allogeneic native iNKT cell therapy / Oncology and Immunology
    Critical pulmonary immune failure (severe hypoxemic respiratory failure/pneumonia/ARDS)Phase 2randomized adaptive placebo-controlled ongoingUSSolid tumor cancers (checkpoint-refractory, incl. gastric/esophageal/GEJ adenocarcinoma)Phase 2investigator-sponsored ongoing (NCT06251973)USGraft-versus-host disease (GvHD prevention)expanding development
  • MiNK-215MiNK-215 / FAP / IL-15 armored FAP-CAR-iNKT cell therapy / Oncology
    Solid tumors (NSCLC, CRC liver metastases)PreclinicalIND-enabling studies underway
  • MiNK-413MiNK-413 / BCMA / IL-15 armored BCMA-CAR-iNKT cell therapy / Oncology
    Multiple myelomaPreclinical
  • PRAME TCR-iNKTPRAME / TCR-engineered iNKT cell therapy / Oncology
    Pediatric cancers/solid tumorsPreclinicalIND-enabling

Latest news8 items

All news

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium

First patients treated with agenT-797 were alive and afebrile at endpoint Day 28 with improved oxygenation, infection control and removal from ventilator and vasopressor support Analysis of blood and lung fluid showed signals of infection control and biological changes associated with immune

Presentation / Abstract • Phase 2MHSRS presentation Thu, Aug 6, 2026, 11:30 AM ET

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET.

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trial Sequential immunotherapy with agenT-797 and N-803, an FDA-approved IL-15 superagonist, Anktiva® may provide impactful clinical combination targeting Coccidioides

Presentation / Abstract • Phase 2ATS poster presentation Wed, May 20, 2026
MiNK Therapeutics, Inc. • Endpoint Arena